Primary contact

Affinivax is developing novel vaccines based on its proprietary technology platform, the Multiple Antigen Presenting System (MAPS), which enables the high affinity binding of protective polysaccharides and proteins in a single vaccine and uniquely induces a broad and protective immune response. The final MAPS complex has the potential to deliver novel vaccines that offer broader disease coverage than existing vaccines, as well as protect against infectious diseases for which there are no effective immunization strategies today. The company is rapidly advancing a lead program targeting Streptococcus pneumoniae (pneumococcus), a pathogen that is responsible for significant morbidity and mortality in children and adults worldwide. Affinivax was established based on the knowledge and insights of world-leading experts in the fields of infectious diseases and vaccines. It is backed by an investment from the Bill & Melinda Gates Foundation and has an exclusive license from Boston Children's Hospital for intellectual property related to the MAPS technology platform.
Primary contact

Funding 💰

Total $2.5M
Select investors Bill & Melinda Gates Foundation
Last update: May 13, 2018